Evidence map›Paper›PMID 40733245›Full record

ReviewMolecules (Basel, Switzerland)2025

Boosting AMPs' Power: From Structural Engineering to Nanotechnology-Based Delivery.

Oluwasegun Eric Ajayi, Rosa Bellavita, Lorenzo Emiliano Imbò, Sara Palladino, Simone Braccia, Annarita Falanga, Stefania Galdiero

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Oluwasegun Eric AjayiINTHERAPI Graduate School, Universite de Bourgogne, 21000 Dijon, France.ORCID 0000-0002-4574-6725
Rosa BellavitaDepartment of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.ORCID 0000-0003-2163-5163
Lorenzo Emiliano ImbòDepartment of Agricultural Sciences, University of Naples Federico II, Via Università 100, Portici, 80055 Portici, Italy.
Sara PalladinoDepartment of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.ORCID 0009-0003-6255-8800
Simone BracciaDepartment of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
Annarita FalangaDepartment of Agricultural Sciences, University of Naples Federico II, Via Università 100, Portici, 80055 Portici, Italy.ORCID 0000-0001-6538-8585
Stefania GaldieroDepartment of Pharmacy, School of Medicine, University of Naples Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.ORCID 0000-0002-7849-7024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) represent a powerful support to conventional antibiotics in addressing the global challenge of antimicrobial resistance (AMR). Their broad-spectrum antimicrobial activity and unique mechanisms of action enable diverse potential applications, including combating multidrug-resistant pathogens, immune modulation, and cancer therapy. Their clinical implementation is hindered by challenges such as toxicity, instability, and high production costs. Recent advances in AMP design, optimization, and delivery mechanisms such as nanoparticle conjugation and rational engineering have enhanced their efficacy, stability, and specificity. Integrating AMPs into precision medicine and combining them with existing therapies promises to overcome current limitations. With ongoing advancements, AMPs have the potential to redefine infection management and possibly other medical problems.

Indexed as

Antimicrobial PeptidesDrug Delivery SystemsNanotechnologyAnimalsAnti-Bacterial AgentsHumansNanoparticlesAnti-Bacterial AgentsAntimicrobial Peptidesantimicrobial peptidesbiofilmsdrug deliverynanoparticle conjugationpeptide strategies

Identifiers

PMID40733245
PMCPMC12298786

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.